Hi, what are you looking for?
The price for NeuroDerm, the largest ever acquisition of an Israeli pharmaceuticals company, reflects a 17% premium on the share price on July 21
Israel’s NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, ended the year on a really high note...
– Israel’s NeuroDerm, which has developed a transdermal drug delivery system for the treatment of Parkinson’s disease, held a less than stellar IPO on...
– The Israeli Parkinson’s disease treatment developer is seeking $58-72 million at a company value of $290 million. – Rehovot-based NeuroDerm, which has...
NeuroDerm Ltd., an Israeli clinical stage pharmaceutical company which develops drugs for central nervous system (CNS) diseases, announced the launch of its initial public...
NeuroDerm, an Israeli clinical-stage pharmaceutical company, announced that patients with moderate to severe Parkinson’s disease who received continuous, subcutaneous doses of liquid levodopa/carbidopa (LD/CD)...
Israel’s NeuroDerm Ltd., announced that it raised $16 million to further the clinical and regulatory development of its Levodopa products, combating Parkinson’s disease. ND0612L, NeuroDerm’s...
– The company has two products in clinical trials for the treatment of Parkinson’s. – – Transdermal drug delivery system developer Neuroderm Ltd. has filed a...
Mitsubishi has already started seeking technologies in the automotive, smart mobility and other fields. Japanese investments in Israel over the past four years have...
The largest amount ever paid for an Israeli company in the medical sector. Over 200 of Mazor's robotic spinal surgery guidance systems are in...